Trends in relative survival for ovarian cancer from 1975 to 2011

Obstetrics and Gynecology

Volumn 125, Issue 6, 2015, Pages 1345-1352

  Wright, Jason D ^a   Chen, Ling ^a   Tergas, Ana I ^a   Patankar, Sonali ^a   Burke, William M ^a   Hou, June Y ^a   Neugut, Alfred I ^a   Ananth, Cande V ^a   Hershman, Dawn L ^a  

^a Departments of Obstetrics and Gynecology and Medicine and the Herbert Irving Comprehensive Cancer Center Columbia University College of Physicians and Surgeons the Department of Epidemiology Mailman School of Public Health Columbia University and New York Presbyterian Hospital New York New York ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; PRIORITY JOURNAL; RACE; RELATIVE SURVIVAL; SURVIVAL RATE; VERY ELDERLY; AFRICAN AMERICAN; CANCER REGISTRY; CAUCASIAN; ETHNOLOGY; MORTALITY; OVARY TUMOR; PATHOLOGY; STATISTICS AND NUMERICAL DATA; TRENDS; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 84929926126     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000854     Document Type: Article

References (38)

1. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-6.
2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
5. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
6. Life expectancy, United States of America. Available at: https://http://www.google.com/webhp?sourceid5chrome-instant&rlz51C5ACMJ-enUS518US558&ion51&espv52& ie5UTF-8-q5life%20expectancy%20in%20the%20united%20states. Retrieved October 13, 2014.
7. Yin D, Morris CR, Bates JH, German RR. Effect of misclassi-fied underlying cause of death on survival estimates of colon and rectal cancer. J Natl Cancer Inst 2011;103:1130-3.
8. Percy C, Stanek E III, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981;71:242-50.
9. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst 2013;105:1806-13.
10. Hinchliffe SR, Rutherford MJ, Crowther MJ, Nelson CP, Lambert PC. Should relative survival be used with lung cancer data? Br J Cancer 2012;106:1854-9.
11. Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011;29:1570-7.
12. Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol 1994;10:2-6.
13. Gamel JW, Vogel RL. Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res 2001;10:339-52.
14. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program SEER∗Stat database: incidence- SEER 18 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2013 Sub (1973-2011 varying)-linked to county attributes-total U.S., 1969-2012 counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission. Available at: http://www.seer.cancer.gov. Retrieved July 28, 2014.
15. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Technical, end results evaluation section. Bethesda (MD): National Cancer Institute; 1959.
16. Surveillance Research Program, National Cancer Institute SEER∗Stat software version 8.1.5. Available at: http://www. seer.cancer.gov/seerstat. Retrieved July 28, 2014.
17. Estimating and modeling relative survival using SAS. Available at: http://www.pauldickman.com/survival/sas/relative-survival- using-sas.pdf. Retrieved August 13, 2014.
18. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004;23:51-64.
19. Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. J R Stat Soc Ser C Appl Stat 1987;36:309-17.
20. Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol 2012;125: 19-24.
21. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 2008;112: 2289-300.
22. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1): S161-92.
23. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol 2012;125:649-54.
24. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012;120:612-8.
25. Akhtar-Danesh N, Elit L, Lytwyn A. Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study. Gynecol Oncol 2011;123:192-5.
26. Akeson M, Jakobsen AM, Zetterqvist BM, Holmberg E, Brännström M, Horvath G. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer 2009;19:116-23.
27. Hannibal CG, Cortes R, Engholm G, Kjaer SK. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand 2008;87:1353-60.
28. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:125-32.
29. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113-25.
30. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322:1021-7.
31. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53.
32. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6.
33. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
34. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
35. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32: 1302-8.
36. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305: 2295-303.
37. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
38. Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer 2014;120: 1246-54.